Center-Authored Papers

Filters: Author is Persky, Daniel O  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
Gustafson HL, Yao S, Goldman BH, Lee K, Spier CM, Leblanc ML, Rimsza LM, Cerhan JR, Habermann TM, Link BK et al..  2014.  Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma.. American journal of hematology. Abstract
L
Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros JL et al..  2017.  Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2017722157. Abstract
M
Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, Fisher RI, Miller TP.  2012.  Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.. Cancer. Abstract
P
Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, LeBlanc M, Maloney DG, Press OW, Miller TP, Rimsza LM.  2012.  Reply to "Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story?" Haematologica. 2012;97(11):e45. Haematologica. 97(11):e46.
Persky DO, Dornan D, Goldman B, Braziel R, Fisher R, LeBlanc M, Maloney DG, Press O, Miller T, Rimsza LM.  2012.  Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.. Haematologica. 97(6):937-942. Abstract
Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP.  2008.  Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(14):2258-63. Abstract
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea DB, Press OW, Constine LS, Barton KP, Friedberg JW et al..  2015.  Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.. Blood. 125(2):236-41. Abstract
Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox A-M et al..  2016.  A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.. Leukemia & lymphoma. 57(10):2359-2369. Abstract
R
Rimsza LM, LeBlanc M, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM et al..  2008.  Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.. Blood. 112(8):3425-33. Abstract
S
Stasik CJ, Nitta H, Zhang W, Mosher CH, Cook JR, Tubbs RR, Unger JM, Brooks TA, Persky DO, Wilkinson ST et al..  2010.  Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma.. Haematologica. 95(4):597-603. Abstract
Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, LeBlanc M, Fisher RI, Miller TP.  2009.  A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.. Leukemia & lymphoma. 50(5):728-35. Abstract